The United Kingdom and the United States have reached a landmark trade agreement that will keep zero tariffs on British drug shipments being sold in the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to raise funding on medicines through the public health system. This pledge secures that tariffs on these key exports will be held at nothing for a duration of three years.
This deal is in response to previous threats to hike import taxes on branded drug products, with figures floated up to double the cost.
"This arrangement between the United Kingdom bolsters the international landscape for new treatments and establishes long-overdue equity to American-British medicine commerce," a statement said.
Trade Significance
Medicines represent one of the the United Kingdom's most significant exports to the America, which is by far the biggest market for leading companies like GSK and AstraZeneca.
Export figures reveal that in the year leading up to last September, the UK exported pharmaceutical products valued at billions to the US. This figure made up a significant portion of British export trade in that timeframe.
"This deal safeguards work, increases capital expenditure and sets the stage for the UK to become a global hub for medical research," the Business and Trade Secretary commented.
Key UK Commitments
The deal involves several key changes from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new therapies to be too expensive by 25%.
- Boosted Medicine Funding: There is a aim to double overall public funding on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Payback Limit: The sum pharmaceutical firms must return to the NHS to prevent overspending will be restricted at fifteen percent. In the past, refunds exceeded twenty percent.
Industry Background
The pact takes place against a protracted tension between the pharmaceutical industry and the British authorities over drug pricing and approval rates.
The disagreement were heightened by claims that US patients were paying several times more for the identical medicines than people in the UK and Europe.
Recently, several major drug company projects in the UK have been delayed or abandoned, while substantial funding commitments have been directed toward projects in the United States.
A senior figure acknowledged that the NHS had to spend more on medicines, noting that its expenditure on drugs had shrunk as a proportion of its resources over the previous ten-year period.
